Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

2(33.3%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 3(2)

Phase 2(2)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06365788Phase 2Recruiting

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Role: collaborator

NCT01447732Phase 1Completed

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Role: collaborator

NCT02311764Phase 2Terminated

Carboplatin in Castration-resistant Prostate Cancer

Role: collaborator

NCT01935492Phase 3Completed

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer

Role: collaborator

NCT02713100Unknown

Self Reported Level of Agitation of Patients Presenting to an Emergency Department

Role: collaborator

NCT01741285Phase 4Completed

Effects of QVAR in Smokers With Asthma

Role: collaborator

NCT02805842Phase 3Unknown

Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus

Role: collaborator

NCT01555944Completed

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

Role: lead

All 8 trials loaded